Fredun Pharmaceuticals Hits New 52-Week High of Rs. 1877.4

Fredun Pharmaceuticals has reached a significant milestone by hitting a new 52-week high of Rs. 1877.4 today, marking a notable achievement for the microcap company in the Pharmaceuticals & Biotechnology sector. This new high reflects a robust performance, as the stock has outperformed its sector by 5.04% and has gained 10.25% over the past two days. The stock opened with a gain of 3.47% today and reached an intraday high of Rs. 1877.4, showcasing strong momentum. Fredun Pharmaceuticals has consistently traded above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price performance. Over the past year, Fredun Pharmaceuticals has delivered an impressive return of 179.71%, significantly outpacing the Sensex, which has grown by only 9.22% during the same period. The company has also reported substantial growth in key financial metrics, including a 127.87% increase in net profit and a 39.73% annual growth rate in net sales. This performance underscores Fredun Pharmaceuticals' strong market position and operational efficiency.